Institutional Investors Increase AstraZeneca Holdings in Q3 2025
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter, with AMG National Trust Bank, Cibc World Market Inc., and Advisors Asset Management Inc. increasing holdings by approximately 20%.
Several institutional investors increased their positions in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to recent Form 13F filings with the Securities & Exchange Commission. AMG National Trust Bank increased its position by 20.4% during the third quarter, acquiring an additional 7,289 shares. The firm owned 42,983 shares of the company's stock after the purchase, with holdings valued at $3,298,000 at the end of the most recent quarter.
Cibc World Market Inc. lifted its stake by 21.5% during the third quarter, purchasing an additional 11,398 shares during the quarter. The firm owned 64,421 shares of the company's stock after the purchase, with holdings valued at $4,942,000 at the end of the most recent quarter.
Advisors Asset Management Inc. lifted its holdings by 20.2% in the third quarter, buying an additional 8,453 shares during the period. The fund owned 50,365 shares of the company's stock after the purchase, with holdings valued at $3,864,000 at the end of the most recent quarter.
Other institutional investors also made significant changes to their positions during the second quarter. Fayez Sarofim & Co grew its stake by 173.4%, acquiring an additional 2,376,032 shares. The firm now owns 3,745,902 shares valued at $261,764,000. Acadian Asset Management LLC grew its position by 2,389.9%, buying an additional 1,961,764 shares. The firm now owns 2,043,850 shares worth $142,798,000.
Jennison Associates LLC increased its holdings by 15.2%, buying an additional 1,605,133 shares. The firm now owns 12,167,365 shares valued at $850,255,000. Raymond James Financial Inc. lifted its position by 64.8%, acquiring an additional 1,487,662 shares. The firm now owns 3,783,251 shares valued at $264,373,000. Ontario Teachers Pension Plan Board bought a new stake worth $96,936,000.
Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca stock opened at $205.47 on Friday. The company has a one year low of $122.48 and a one year high of $206.71. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. The company has a market capitalization of $318.66 billion, a price-to-earnings ratio of 68.26, a PEG ratio of 1.59 and a beta of 0.34.
The company recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th.
Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. The company currently has an average rating of "Moderate Buy" and a consensus price target of $95.75.
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.